Talat Imran

All filings by Talat Imran on record concern Rani Therapeutics Holdings, Inc., in the capacity of chief executive. We count 20 filings; the first trade dates from 3 February 2022 and the latest from 27 September 2026.

Market trades split into 7 purchases (€120k) and 1 sale (€11k). Netting one side against the other leaves €109k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 10 share grants. Since January 2026: 1 purchase and 1 sale on the market.

Half of the purchases are above €19k and half below. On 3 out of 7 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 29 September 2026 with a share grant (€5,290) in Rani Therapeutics Holdings, Inc. The latest purchase dates back some time: it was published 95 days ago, on 21 July 2026. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.